Reported Earnings • Aug 01
Second quarter 2026 earnings released: EPS: Rp4.46 (vs Rp2.64 in 2Q 2025) Second quarter 2026 results: EPS: Rp4.46 (up from Rp2.64 in 2Q 2025). Revenue: Rp1.29t (up 34% from 2Q 2025). Net income: Rp243.9b (up 70% from 2Q 2025). Profit margin: 19% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 65% per year, which means it is well ahead of earnings. Recent Insider Transactions • Jun 28
President Director recently bought Rp4.0b worth of stock On the 22nd of June, Haryanto Tjiptodihardjo bought around 3m shares on-market at roughly Rp1,614 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Haryanto has been a buyer over the last 12 months, purchasing a net total of Rp11b worth in shares. Announcement • May 05
PT Impack Pratama Industri Tbk, Annual General Meeting, Jun 10, 2026 PT Impack Pratama Industri Tbk, Annual General Meeting, Jun 10, 2026. Reported Earnings • Apr 03
Full year 2025 earnings released: EPS: Rp11.39 (vs Rp9.94 in FY 2024) Full year 2025 results: EPS: Rp11.39 (up from Rp9.94 in FY 2024). Revenue: Rp4.27t (up 10% from FY 2024). Net income: Rp620.0b (up 15% from FY 2024). Profit margin: 14% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Feb 03
PT Impack Pratama Industri Tbk (IDX:IMPC) announces an Equity Buyback for 166,131,000 shares, representing 0.3% for IDR 500,000 million. PT Impack Pratama Industri Tbk (IDX:IMPC) announces an share repurchase program. Under the program the company will repurchase up to 166,131,000 shares, representing 0.30% for IDR 500,000 million. The sources of program is using the internal funds of the company. The program will valid till May 2, 2026. Recent Insider Transactions • Nov 19
Board Member recently bought Rp2.0b worth of stock On the 14th of November, Phillip Tjipto bought around 750k shares on-market at roughly Rp2,600 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth Rp6.8b. Insiders have collectively bought Rp15b more in shares than they have sold in the last 12 months. New Risk • Nov 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indonesian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Recent Insider Transactions • Oct 30
President Director recently bought Rp6.8b worth of stock On the 28th of October, Haryanto Tjiptodihardjo bought around 3m shares on-market at roughly Rp2,273 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Haryanto's only on-market trade for the last 12 months. Board Change • Oct 14
No independent directors There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. No independent directors (7 non-independent directors). Independent Commissioner Irawan Soerodjo was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Sep 23
PT Impack Pratama Industri Tbk announced that it has received IDR 486 billion in funding from Kaddara Pte. Ltd, PT Ranca Maya Raya PT Impack Pratama Industri Tbk announced private placement of 600,000,000 common shares at an issue price of IDR 810 per share for gross proceeds of IDR 486,000,000,000 on September 21, 2025. The transaction included participation from new investors Kaddara Pte. Ltd for 350,000,000 shares for proceeds of IDR 283,500,000,000, PT Ranca Maya Raya for 190,000,000 shares for proceeds of IDR 153,900,000,000, Field Tree Limited for 60,000,000 shares for proceeds of IDR 48,600,000,000. The issue price is lower than the market price which closed at IDR 1620 per share. Following the issuance of new shares, IMPC's total issued and fully paid-up shares increased from 54.26 billion to 54.86 billion. Announcement • Apr 18
PT Impack Pratama Industri Tbk, Annual General Meeting, May 26, 2025 PT Impack Pratama Industri Tbk, Annual General Meeting, May 26, 2025. Reported Earnings • Nov 02
Third quarter 2024 earnings released: EPS: Rp2.40 (vs Rp2.35 in 3Q 2023) Third quarter 2024 results: EPS: Rp2.40 (up from Rp2.35 in 3Q 2023). Revenue: Rp981.1b (up 41% from 3Q 2023). Net income: Rp130.4b (up 2.2% from 3Q 2023). Profit margin: 13% (down from 18% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. New Risk • Oct 17
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (23% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows. Price Target Changed • Sep 04
Price target decreased by 18% to Rp350 Down from Rp425, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of Rp334. Stock is up 3.1% over the past year. The company is forecast to post earnings per share of Rp9.20 for next year compared to Rp14.85 last year. Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: Rp2.18 (vs Rp1.70 in 2Q 2023) Second quarter 2024 results: EPS: Rp2.18 (up from Rp1.70 in 2Q 2023). Revenue: Rp689.9b (up 6.8% from 2Q 2023). Net income: Rp118.4b (up 29% from 2Q 2023). Profit margin: 17% (up from 14% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 4.1% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. New Risk • Jul 11
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 121% Dividend yield: 1.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Recent Insider Transactions • Jul 05
Director of Marketing & Director recently bought Rp437m worth of stock On the 2nd of July, Janto Salim bought around 1m shares on-market at roughly Rp336 per share. This transaction amounted to 4.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Rp3.8b more in shares than they have sold in the last 12 months. Buy Or Sell Opportunity • Jul 02
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to Rp328. The fair value is estimated to be Rp423, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 58%. Revenue is forecast to grow by 24% in a year. Earnings are forecast to grow by 17% in the next year. Buy Or Sell Opportunity • May 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.0% to Rp362. The fair value is estimated to be Rp461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 61%. Revenue is forecast to grow by 41% in 2 years. Earnings are forecast to grow by 42% in the next 2 years. Recent Insider Transactions • May 03
Director of Marketing & Director recently bought Rp174m worth of stock On the 29th of April, Janto Salim bought around 500k shares on-market at roughly Rp348 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth Rp475m. Insiders have collectively bought Rp3.4b more in shares than they have sold in the last 12 months. Reported Earnings • May 03
First quarter 2024 earnings released: EPS: Rp2.74 (vs Rp2.23 in 1Q 2023) First quarter 2024 results: EPS: Rp2.74 (up from Rp2.23 in 1Q 2023). Revenue: Rp744.2b (flat on 1Q 2023). Net income: Rp148.5b (up 23% from 1Q 2023). Profit margin: 20% (up from 16% in 1Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 2.7% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Apr 18
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.0% to Rp370. The fair value is estimated to be Rp464, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 61%. Recent Insider Transactions • Apr 08
Director of Marketing & Director recently bought Rp177m worth of stock On the 2nd of April, Janto Salim bought around 500k shares on-market at roughly Rp355 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth Rp475m. Insiders have collectively bought Rp3.2b more in shares than they have sold in the last 12 months. Buy Or Sell Opportunity • Apr 02
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to Rp360. The fair value is estimated to be Rp461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 61%. Reported Earnings • Mar 31
Full year 2023 earnings released: EPS: Rp14.85 (vs Rp5.77 in FY 2022) Full year 2023 results: EPS: Rp14.85 (up from Rp5.77 in FY 2022). Revenue: Rp2.86t (up 1.8% from FY 2022). Net income: Rp430.5b (up 40% from FY 2022). Profit margin: 15% (up from 11% in FY 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 42% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Feb 24
Key Executive recently bought Rp475m worth of stock On the 19th of February, - Lisan bought around 1m shares on-market at roughly Rp380 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was -'s only on-market trade for the last 12 months. Reported Earnings • Nov 02
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: Rp696.7b (up 2.5% from 3Q 2022). Net income: Rp127.6b (up 111% from 3Q 2022). Profit margin: 18% (up from 8.9% in 3Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 7.8% growth forecast for the Chemicals industry in Indonesia. Reported Earnings • Aug 01
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: Rp645.9b (flat on 2Q 2022). Net income: Rp92.1b (up 45% from 2Q 2022). Profit margin: 14% (up from 9.8% in 2Q 2022). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in Asia. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to Rp400, the stock trades at a trailing P/E ratio of 62.7x. Average forward P/E is 15x in the Chemicals industry in Indonesia. Total returns to shareholders of 284% over the past three years. Reported Earnings • Apr 01
Full year 2022 earnings released: EPS: Rp63.43 (vs Rp43.46 in FY 2021) Full year 2022 results: EPS: Rp63.43 (up from Rp43.46 in FY 2021). Revenue: Rp2.81t (up 26% from FY 2021). Net income: Rp307.4b (up 46% from FY 2021). Profit margin: 11% (up from 9.4% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: No independent directors. 7 non-independent directors. Independent Commissioner Kelvin Lee was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Reported Earnings • Aug 01
Second quarter 2022 earnings released: EPS: Rp13.16 (vs Rp8.72 in 2Q 2021) Second quarter 2022 results: EPS: Rp13.16 (up from Rp8.72 in 2Q 2021). Revenue: Rp645.9b (up 28% from 2Q 2021). Net income: Rp63.6b (up 51% from 2Q 2021). Profit margin: 9.8% (up from 8.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 4.4%, compared to a 8.5% growth forecast for the industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Independent Commissioner Kelvin Lee was the last independent director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • May 05
Investor sentiment improved over the past week After last week's 16% share price gain to Rp1,720, the stock trades at a trailing P/E ratio of 61.7x. Average trailing P/E is 16x in the Chemicals industry in Indonesia. Total returns to shareholders of 76% over the past three years. Is New 90 Day High Low • Feb 20
New 90-day high: Rp1,485 The company is up 7.0% from its price of Rp1,390 on 20 November 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 17% over the same period. Is New 90 Day High Low • Feb 02
New 90-day high: Rp1,450 The company is up 7.0% from its price of Rp1,360 on 05 November 2020. The Indonesian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 26% over the same period. Upcoming Dividend • Oct 28
Upcoming Dividend of Rp10.00 Per Share Will be paid on the 13th of November to those who are registered shareholders by the 4th of November. The trailing yield of 0.7% is below the top quartile of Indonesian dividend payers (6.4%), but is in line with industry peers (0.7%). Is New 90 Day High Low • Oct 27
New 90-day high: Rp1,340 The company is up 6.0% from its price of Rp1,260 on 29 July 2020. The Indonesian market is flat over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 6.0% over the same period. Reported Earnings • Oct 24
Third quarter earnings released Over the last 12 months the company has reported total profits of Rp134.8b, up 34% from the prior year. Total revenue was Rp1.69t over the last 12 months, up 14% from the prior year. Is New 90 Day High Low • Sep 30
New 90-day high: Rp1,280 The company is up 2.0% from its price of Rp1,250 on 02 July 2020. The Indonesian market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 13% over the same period. 
